Cargando…
Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
INTRODUCTION: The clinical benefits of biologic and oral treatments for moderate-to-severe plaque psoriasis are well-established, but efficacy outcomes can vary across therapies. Comparative efficacy analysis can be highly informative in clinical settings with multiple therapeutic options. This stud...
Autores principales: | Armstrong, April W., Soliman, Ahmed M., Betts, Keith A., Wang, Yan, Gao, Yawen, Puig, Luis, Augustin, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163943/ https://www.ncbi.nlm.nih.gov/pubmed/33788177 http://dx.doi.org/10.1007/s13555-021-00511-1 |
Ejemplares similares
-
Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
por: Armstrong, April W., et al.
Publicado: (2021) -
A Response to: Letter to the Editor Regarding Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
por: Armstrong, April W., et al.
Publicado: (2022) -
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
por: Armstrong, April, et al.
Publicado: (2022) -
Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
por: Egeberg, Alexander, et al.
Publicado: (2023) -
Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis
por: Armstrong, April W., et al.
Publicado: (2023)